Hereditary Leiomyomatosis and Renal Cell Carcinoma

Oncology·MeSH: Hereditary leiomyomatosis and renal cell cancer

Prevalence

48.0 / 100K

Incidence

15.0 / 100K/yr

5 drugs in development·2 companies·1 clinical trial

Drug Pipeline by Phase

Compare drugs

Frequently asked questions

How many drugs are in development for Hereditary Leiomyomatosis and Renal Cell Carcinoma?

BioSniper tracks 5 drugs in development for Hereditary Leiomyomatosis and Renal Cell Carcinoma across 2 companies.

How many clinical trials target Hereditary Leiomyomatosis and Renal Cell Carcinoma?

There are 1 clinical trial targeting Hereditary Leiomyomatosis and Renal Cell Carcinoma tracked by BioSniper.

What is the prevalence of Hereditary Leiomyomatosis and Renal Cell Carcinoma?

The estimated prevalence of Hereditary Leiomyomatosis and Renal Cell Carcinoma is approximately 48.0 per 100,000 population.

Deep-dive into Hereditary Leiomyomatosis and Renal Cell Carcinoma

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Hereditary Leiomyomatosis and Renal Cell Carcinoma — Drugs in Development & Clinical Trials | BioSniper